- Home
- ZURA
ZURA
Zura Bio Limited
as 03-26-2025 1:37pm EST
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $15.80 | AVG Volume (30 days): | 244.4K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $6.35 | Next Earning Date: | 03-25-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Zura Bio Limited News
ZURA Breaking Stock News: Dive into ZURA Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
Business Wire
a month ago
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
Simply Wall St.
2 months ago
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth
Business Wire
3 months ago
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Business Wire
4 months ago
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Business Wire
4 months ago
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Business Wire
5 months ago
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Business Wire
5 months ago
Zura Bio to Participate in Two Upcoming Investor Conferences in November
Compare ZURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZURA Zura Bio Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.